CU20160058A7 - Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular - Google Patents

Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular

Info

Publication number
CU20160058A7
CU20160058A7 CUP2016000058A CU20160058A CU20160058A7 CU 20160058 A7 CU20160058 A7 CU 20160058A7 CU P2016000058 A CUP2016000058 A CU P2016000058A CU 20160058 A CU20160058 A CU 20160058A CU 20160058 A7 CU20160058 A7 CU 20160058A7
Authority
CU
Cuba
Prior art keywords
central
nervous system
benzodiazepina
activity
derived
Prior art date
Application number
CUP2016000058A
Other languages
English (en)
Spanish (es)
Inventor
Fernández Pedro Gilberto Bárzaga
Hernández René Delgado
Fonseca Luis Arturo Fonseca
Suárez Bárbara Beatriz Garrido
Alfonso Nicté González
Figueredo Yanier Nuñez
Rodríguez Estael Ochoa
Yaquis Alejandro Saúl Padrón
Andreu Gilberto Lázaro Pardo
Sánchez Jeney Ramírez
Reyes Yamila Verdecia
Guerra Maylin Wong
Original Assignee
Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp
Facultad De Química Univ De La Habana Ministerio De Educacion Superior (Mes)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp, Facultad De Química Univ De La Habana Ministerio De Educacion Superior (Mes) filed Critical Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp
Priority to CUP2016000058A priority Critical patent/CU20160058A7/xx
Priority to KR1020187035040A priority patent/KR102428383B1/ko
Priority to ES17732729T priority patent/ES2902992T3/es
Priority to CN201780041572.6A priority patent/CN110114356B/zh
Priority to NZ748959A priority patent/NZ748959A/en
Priority to AU2017259748A priority patent/AU2017259748B2/en
Priority to SG11201809845TA priority patent/SG11201809845TA/en
Priority to EP17732729.3A priority patent/EP3470414B1/en
Priority to JP2019510748A priority patent/JP7078959B2/ja
Priority to PCT/CU2017/050002 priority patent/WO2017190713A1/es
Priority to EA201892461A priority patent/EA201892461A1/ru
Priority to MX2018013405A priority patent/MX2018013405A/es
Priority to CA3023105A priority patent/CA3023105C/en
Priority to SI201731044T priority patent/SI3470414T1/sl
Priority to BR112018072588-9A priority patent/BR112018072588B1/pt
Priority to US16/099,116 priority patent/US11098039B2/en
Priority to DK17732729.3T priority patent/DK3470414T3/da
Priority to ARP170101152A priority patent/AR108369A1/es
Publication of CU20160058A7 publication Critical patent/CU20160058A7/xx
Priority to CL2018003113A priority patent/CL2018003113A1/es
Priority to ZA2018/08162A priority patent/ZA201808162B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CUP2016000058A 2016-05-04 2016-05-04 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular CU20160058A7 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CUP2016000058A CU20160058A7 (es) 2016-05-04 2016-05-04 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
PCT/CU2017/050002 WO2017190713A1 (es) 2016-05-04 2017-05-03 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
EA201892461A EA201892461A1 (ru) 2016-05-04 2017-05-03 Продукт бензодиазепина с активностью на центральную нервную и сердечно-сосудистую системы
CN201780041572.6A CN110114356B (zh) 2016-05-04 2017-05-03 具有对中枢神经系统和血管系统的活性的苯并二氮卓衍生物
NZ748959A NZ748959A (en) 2016-05-04 2017-05-03 Benzodiazepine derivative with activity on the central nervous and vascular systems
AU2017259748A AU2017259748B2 (en) 2016-05-04 2017-05-03 Benzodiazepine derivative with activity on the central nervous and vascular systems
SG11201809845TA SG11201809845TA (en) 2016-05-04 2017-05-03 Benzodiazepine product with activity on the central nervous and vascular systems
EP17732729.3A EP3470414B1 (en) 2016-05-04 2017-05-03 Benzodiazepine derivative with activity on the central nervous and vascular systems
JP2019510748A JP7078959B2 (ja) 2016-05-04 2017-05-03 中枢神経系及び血管系での活性を持つベンゾジアゼピン誘導体
KR1020187035040A KR102428383B1 (ko) 2016-05-04 2017-05-03 중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물
ES17732729T ES2902992T3 (es) 2016-05-04 2017-05-03 Derivado de benzodiazepina con actividad sobre los sistemas vascular y nervioso central
MX2018013405A MX2018013405A (es) 2016-05-04 2017-05-03 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular.
CA3023105A CA3023105C (en) 2016-05-04 2017-05-03 Benzodiazepine derivative with activity on the central nervous and vascular systems
SI201731044T SI3470414T1 (sl) 2016-05-04 2017-05-03 Derivat benzodiazepina, ki deluje na centralni živčni in žilni sistem
BR112018072588-9A BR112018072588B1 (pt) 2016-05-04 2017-05-03 Uso de um composto de benzodiacepina
US16/099,116 US11098039B2 (en) 2016-05-04 2017-05-03 Benzodiazepine product with activity on the central nervous and vascular systems
DK17732729.3T DK3470414T3 (da) 2016-05-04 2017-05-03 Benzodiazepinderivat med aktivitet på centralnerve- og karsystemerne
ARP170101152A AR108369A1 (es) 2016-05-04 2017-05-04 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
CL2018003113A CL2018003113A1 (es) 2016-05-04 2018-10-31 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular.
ZA2018/08162A ZA201808162B (en) 2016-05-04 2018-12-03 Benzodiazepine derivative with activity on the central nervous and vascular systems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2016000058A CU20160058A7 (es) 2016-05-04 2016-05-04 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular

Publications (1)

Publication Number Publication Date
CU20160058A7 true CU20160058A7 (es) 2017-12-08

Family

ID=59215419

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000058A CU20160058A7 (es) 2016-05-04 2016-05-04 Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular

Country Status (20)

Country Link
US (1) US11098039B2 (xx)
EP (1) EP3470414B1 (xx)
JP (1) JP7078959B2 (xx)
KR (1) KR102428383B1 (xx)
CN (1) CN110114356B (xx)
AR (1) AR108369A1 (xx)
AU (1) AU2017259748B2 (xx)
BR (1) BR112018072588B1 (xx)
CA (1) CA3023105C (xx)
CL (1) CL2018003113A1 (xx)
CU (1) CU20160058A7 (xx)
DK (1) DK3470414T3 (xx)
EA (1) EA201892461A1 (xx)
ES (1) ES2902992T3 (xx)
MX (1) MX2018013405A (xx)
NZ (1) NZ748959A (xx)
SG (1) SG11201809845TA (xx)
SI (1) SI3470414T1 (xx)
WO (1) WO2017190713A1 (xx)
ZA (1) ZA201808162B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021139842A2 (es) 2019-12-26 2021-07-15 Centro de Investigación Y Desarrollo de Medicamentos CIDEM Uso de un derivado benzodiacepínico y método de tratamiento del trauma craneoencefálico
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288070A1 (en) * 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
CU20090172A6 (es) 2009-10-09 2011-10-05 Facultad De Quimica Universidad De La Habana Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
CU24576B1 (es) 2016-05-04 2022-02-04 Centro De Investig Y Desarrollo De Medicamentos Cidem Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Also Published As

Publication number Publication date
EP3470414B1 (en) 2021-10-13
WO2017190713A1 (es) 2017-11-09
AU2017259748A1 (en) 2018-12-20
EP3470414A1 (en) 2019-04-17
NZ748959A (en) 2024-02-23
KR20210025137A (ko) 2021-03-09
MX2018013405A (es) 2019-08-16
CN110114356A (zh) 2019-08-09
BR112018072588B1 (pt) 2024-02-20
CA3023105C (en) 2023-07-18
BR112018072588A2 (pt) 2019-02-19
JP2019519600A (ja) 2019-07-11
AR108369A1 (es) 2018-08-15
AU2017259748B2 (en) 2021-08-05
ZA201808162B (en) 2021-08-25
KR102428383B1 (ko) 2022-08-02
CL2018003113A1 (es) 2019-04-12
SI3470414T1 (sl) 2022-03-31
EA201892461A1 (ru) 2019-04-30
CN110114356B (zh) 2021-09-24
US11098039B2 (en) 2021-08-24
SG11201809845TA (en) 2018-12-28
JP7078959B2 (ja) 2022-06-01
ES2902992T3 (es) 2022-03-30
DK3470414T3 (da) 2022-01-17
US20190270738A1 (en) 2019-09-05
CA3023105A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
NI201800124A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2018012485A2 (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2020002992A2 (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
CL2020002038A1 (es) Oligonucleótidos para modular la expresión de tmem106b.
CU20160058A7 (es) Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CU20160141A7 (es) Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
ECSP21034281A (es) Compuesto de 1,3,4-oxadiazolona y fármaco
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
BR112018017058A2 (pt) 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1
UY36305A (es) Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales.